187 related articles for article (PubMed ID: 24951469)
1. Challenges and promises in modeling dermatologic disorders with bioengineered skin.
Eungdamrong NJ; Higgins C; Guo Z; Lee WH; Gillette B; Sia S; Christiano AM
Exp Biol Med (Maywood); 2014 Sep; 239(9):1215-24. PubMed ID: 24951469
[TBL] [Abstract][Full Text] [Related]
2. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
Chang R; Emami K; Wu H; Sun W
Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
[TBL] [Abstract][Full Text] [Related]
3. Skin Diseases Modeling using Combined Tissue Engineering and Microfluidic Technologies.
Mohammadi MH; Heidary Araghi B; Beydaghi V; Geraili A; Moradi F; Jafari P; Janmaleki M; Valente KP; Akbari M; Sanati-Nezhad A
Adv Healthc Mater; 2016 Oct; 5(19):2459-2480. PubMed ID: 27548388
[TBL] [Abstract][Full Text] [Related]
4. Progress and opportunities for tissue-engineered skin.
MacNeil S
Nature; 2007 Feb; 445(7130):874-80. PubMed ID: 17314974
[TBL] [Abstract][Full Text] [Related]
5. [Skin bioengineering: preclinical and clinical applications].
Martínez-Santamaría L; Guerrero-Aspizua S; Del Río M
Actas Dermosifiliogr; 2012; 103(1):5-11. PubMed ID: 21596361
[TBL] [Abstract][Full Text] [Related]
6. Biomimetic cardiac microsystems for pathophysiological studies and drug screens.
Lee J; Razu ME; Wang X; Lacerda C; Kim JJ
J Lab Autom; 2015 Apr; 20(2):96-106. PubMed ID: 25524490
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular human organ-on-a-chip platform for disease modeling, drug development, and personalized therapy.
Khanna A; Oropeza BP; Huang NF
J Biomed Mater Res A; 2024 Apr; 112(4):512-523. PubMed ID: 37668192
[TBL] [Abstract][Full Text] [Related]
8. Progress and Future Prospectives in Skin-on-Chip Development with Emphasis on the use of Different Cell Types and Technical Challenges.
van den Broek LJ; Bergers LIJC; Reijnders CMA; Gibbs S
Stem Cell Rev Rep; 2017 Jun; 13(3):418-429. PubMed ID: 28536890
[TBL] [Abstract][Full Text] [Related]
9. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.
Conant G; Lai BFL; Lu RXZ; Korolj A; Wang EY; Radisic M
Stem Cell Rev Rep; 2017 Jun; 13(3):335-346. PubMed ID: 28429185
[TBL] [Abstract][Full Text] [Related]
10. The use of skin models in drug development.
Mathes SH; Ruffner H; Graf-Hausner U
Adv Drug Deliv Rev; 2014 Apr; 69-70():81-102. PubMed ID: 24378581
[TBL] [Abstract][Full Text] [Related]
11. Bioengineered skin humanized model of psoriasis.
Carretero M; Guerrero-Aspizua S; Del Río M
Methods Mol Biol; 2013; 961():305-23. PubMed ID: 23325653
[TBL] [Abstract][Full Text] [Related]
12. Modeling the lung: Design and development of tissue engineered macro- and micro-physiologic lung models for research use.
Nichols JE; Niles JA; Vega SP; Argueta LB; Eastaway A; Cortiella J
Exp Biol Med (Maywood); 2014 Sep; 239(9):1135-69. PubMed ID: 24962174
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis drug discovery: methods for evaluation of potential drug candidates.
Svensson L; Røpke MA; Norsgaard H
Expert Opin Drug Discov; 2012 Jan; 7(1):49-61. PubMed ID: 22468893
[TBL] [Abstract][Full Text] [Related]
14. The role of body-on-a-chip devices in drug and toxicity studies.
Esch MB; King TL; Shuler ML
Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
[TBL] [Abstract][Full Text] [Related]
15. In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research.
Desmet E; Ramadhas A; Lambert J; Van Gele M
Exp Biol Med (Maywood); 2017 Jun; 242(11):1158-1169. PubMed ID: 28585891
[TBL] [Abstract][Full Text] [Related]
16. Engineered Liver Platforms for Different Phases of Drug Development.
Ware BR; Khetani SR
Trends Biotechnol; 2017 Feb; 35(2):172-183. PubMed ID: 27592803
[TBL] [Abstract][Full Text] [Related]
17. Thinking inside the box: keeping tissue-engineered constructs in vitro for use as preclinical models.
Gibbons MC; Foley MA; Cardinal KO
Tissue Eng Part B Rev; 2013 Feb; 19(1):14-30. PubMed ID: 22800715
[TBL] [Abstract][Full Text] [Related]
18. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
Menshykau D
Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
[TBL] [Abstract][Full Text] [Related]
19. Generation of functional cardiac microtissues in a beating heart-on-a-chip.
Ugolini GS; Visone R; Cruz-Moreira D; Mainardi A; Rasponi M
Methods Cell Biol; 2018; 146():69-84. PubMed ID: 30037467
[TBL] [Abstract][Full Text] [Related]
20. Organ-on-chip models: Implications in drug discovery and clinical applications.
Mittal R; Woo FW; Castro CS; Cohen MA; Karanxha J; Mittal J; Chhibber T; Jhaveri VM
J Cell Physiol; 2019 Jun; 234(6):8352-8380. PubMed ID: 30443904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
